Table 2.

NLR pooled HRs and 95% CIs in meta-analysis for OS and PFS

Stratified analysis	OS								Begg’s test P-value	PFS								Begg’s test P-value
	No. of studies	Chi-squared	Pheterogeneity	I2(%)	Pooled HR (95% CI)					No. of studies	Chi-squared	Pheterogeneity	I2 (%)	HR (95% CI)
					Fixed effect	P-value	Random effect	P-value						Fixed effect	P-value	Random effect	P-value
Overall
	16	23.7	0.07	37.7	1.52 (1.41–1.63)	<0.001	1.59 (1.42–1.77)	<0.001	0.096	7	5.29	0.507	0	1.50 (1.21–1.85)	<0.001	1.50 (1.21–1.85)	<0.001	0.23
Nation
Asian	3	0.43	0.807	0	2.43 (1.47–4.01)	0.001	2.43 (1.47–4.01)	0.001		2	0.31	0.577	0	1.99 (1.30–3.06)	0.002	1.99 (1.30–3.06)	0.002
Non- Asian	13	19.82	0.071	39.5	1.50 (1.40–1.62)	<0.001	1.56 (1.39–1.74)	<0.001		5	2.72	0.606	0	1.36 (1.07–1.74)	0.014	1.36 (1.07–1.74)	0.014
Treatment
First selected	13	16.97	0.151	29.3	1.49 (1.38–1.60)	<0.001	1.53 (1.38–1.70)	<0.001		5	5.14	0.273	22.2	1.51 (1.17–1.95)	0.002	1.55 (1.14–2.10)	0.005
Second selected	3	2.8	0.247	28.5	1.97 (1.51–2.57)	<0.001	1.92 (1.37–2.69)	<0.001		2	0.14	0.706	0	1.48 (1.01–2.17)	0.046	1.48 (1.01–2.17)	0.046
No. of patients
<182	7	1.04	0.984	0	2.16 (1.66–2.80)	<0.001	2.16 (1.66–2.80)	<0.001		6	5.18	0.394	3.4	1.52 (1.20–1.93)	<0.001	1.53 (1.20–1.94)	0.001
≥182	9	15.15	0.056	47.2	1.47 (1/37–1.59)	<0.001	1.50 (1.34–1.69)	<0.001		1	–	–	–	1.38 (0.82–2.32)	0.225	1.38 (0.82–2.32)	0.225
Cutoff
>3.3	7	10.68	0.099	43.8	1.58 (1.38–1.82)	<0.001	1.72 (1.32–2.25)	<0.001		4	0.73	0.867	0	1.87 (1.38–2.54)	<0.001	1.87 (1.38–2.54)	<0.001
≤3.3	9	12.52	0.13	36.1	1.49 (1.37–1.63)	<0.001	1.56 (1.38–1.76)	<0.001		3	0.41	0.814	0	1.20 (0.89–1.62)	0.233	1.20 (0.89–1.62)	0.233

Abbreviations: NLR, neutrophil–lymphocyte ratio; OS, overall survival; PFS, progression-free survival.